Cargando…
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037
PURPOSE: Tumours frequently have defects in multiple oncogenic pathways, e.g. MAPK and PI3K signalling pathways, and combinations of targeted therapies may be required for optimal activity. This study evaluated the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037, as single agents and...
Autores principales: | Haagensen, Emma J., Thomas, Huw D., Schmalix, Wolfgang A., Payne, Andrew C., Kevorkian, Lara, Allen, Rodger A., Bevan, Paul, Maxwell, Ross J., Newell, David R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114336/ https://www.ncbi.nlm.nih.gov/pubmed/27837257 http://dx.doi.org/10.1007/s00280-016-3186-4 |
Ejemplares similares
-
wxPython in action
por: Rappin, Noel, 1971-
Publicado: (2006) -
wxPython in Action
por: Rappin, Noel, et al.
Publicado: (2006) -
WX-132-18B, a novel microtubule inhibitor, exhibits promising anti-tumor effects
por: Guan, Fang, et al.
Publicado: (2017) -
DUF916 and DUF3324 in the WxL protein cluster bind to WxL and link bacterial and host surfaces
por: Hassan, Mahreen U., et al.
Publicado: (2023) -
Sudapyridine (WX-081), a Novel Compound against Mycobacterium tuberculosis
por: Yao, Rong, et al.
Publicado: (2022)